started · updated
Hungary proposes limits on high-cost drug subsidies
A 36-page draft law has been released for public debate in Hungary, aiming to restrict individual discretionary subsidies for particularly expensive medications. The proposal seeks to prevent massive public expenditures on treatments that lack sufficient evidence of efficacy.
Under the new rules, pharmaceutical manufacturers would be required to prove the clinical benefit of their products relative to their cost. The draft proposes capping annual subsidies at ten times the per capita GDP and total treatment subsidies at fifty times the per capita GDP. Because these limits are tied to GDP, the specific monetary thresholds would fluctuate with economic changes.
The National Health Insurance Fund Manager (NEAK) currently uses this discretionary process to finance treatments for rare diseases, cancers, and other severe conditions not yet covered by standard social insurance. The proposed changes could require hospitals to make financial commitments and might influence patient access to medicine based on both the cost of treatment and the financial capacity of the healthcare institution.